Omaha Public Power District, NE's $300M Subordinate Revenue Bonds Rated 'AA-'; Outlook Stable Jun 05

  • ID: 2023694
  • June 2005
  • Standard & Poors
1 of 3

SAN FRANCISCO (Standard & Poor's) June 30, 2005--Standard & Poor's Ratings Services today assigned its 'AA-' rating to Omaha Public Power District (OPPD), Neb.'s proposed $300 million electric system subordinated revenue bonds, or periodically issued bonds (PIBs). Standard & Poor's also affirmed the 'AA' rating on all outstanding revenue bonds at OPPD and the 'A-1+' short-term rating on OPPD's commercial paper program. The 'AA-' rating on the PIBs reflects a subordinate lien position on the revenues of OPPD's electric system. The 'AA' rating on OPPD's outstanding revenue bonds is reflective of the systems strong financial ratios, moderate debt burden, strong operating history, and prudent risk management strategies. "OPPD has maintained stable rates and debt service coverage ratios of more than...

Companies mentioned in this report are:
- Omaha Pub Pwr Dist

Action: Affirmed
Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Omaha Pub Pwr Dist

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.